During the first 30 days after infusion, 95 (77.8%) patients presented an episode of grade 4 neutropenia, with no difference in incidence and duration between early G-CSF and control group (73% vs 80%, p = 0.46, and 5 vs 4 days, p = 0.18, respectively)(Table 2) (Fig. 2). The gene discussed is CSF3; the disease is neutropenia.